BioSpace News Archive

Children’s National Health System (Children’s National) and The HSC Health Care System (HSC) have signed a definitive agreement to create an integrated partnership that will provide seamless care for children and young adults with complex medical needs in Washington, D.C. and across the region.

Health Canada has completed an update to a 2017 safety review on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and has found that the rate of BIA-ALCL in Canada is significantly higher in patients with macro-textured breast implants compared to other implants.

Denver-based ONE Cannabis is building a major growth vehicle that will be taking the industry mainstream: cannabis franchising.

A brand new food supplement to tackle hypertension (high blood pressure) will be available on the market following a license agreement between ProBiotix Health Ltd., a subsidiary of OptiBiotix Health PLc., and Nutrilinea Srl.

CaptSure™ DIY ELISA will complement Expedeon AG’s product offering, as the Company (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) announced today.

IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract and received the downpayment for the delivery of a Proteus®ONE solution with the European Institute of Oncology (IEO) in Milan, Italy.

Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, today announced that the company will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019, at 9:00 a.m. ET

Hoy Health LLC announces that Tampa Bay Wave, an entrepreneurial hub helping tech companies advance their businesses, has officially named Hoy Health among its 2019 selection of diverse companies for its TechDiversity Accelerator program.

Armas Pharmaceuticals Inc. and Micro Labs USA, Inc. have announced, the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market.

Neovasc Inc. announced that the European Heart Journal, Quality of Care and Clinical Outcomes has published a peer-reviewed article indicating the cost effectiveness of the Neovasc Reducer™ as an effective therapy for patients suffering from refractory angina, and its positive impact on healthcare burden.